Inicio › Neuroblastoma › Texas
Ensayos clínicos de Neuroblastoma en Texas
15 estudios sobre Neuroblastoma buscan participantes en Texas.
Ciudades en Texas
Texto oficial del estudio (inglés)
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- University of Texas Southwestern Medical Center, Dallas
Reclutando
Hasta los 17 · Todos los sexos · Actualizado el 13 nov 2026 · NCT06831552Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
ReclutandoFase 1/2
Hasta los 30 · Todos los sexos · Actualizado el 12 nov 2026 · NCT06541262Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- y 10 más
ReclutandoFase 3
Hasta los 30 · Todos los sexos · Actualizado el 30 oct 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
ReclutandoFase 1/2
6 Months – 25 Years · Todos los sexos · Actualizado el 30 oct 2026 · NCT06395103Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
- UT Southwestern, Dallas
- Texas Tech University Health Sciences Center, Lubbock
ReclutandoFase 1
12 Months – 20 Years · Todos los sexos · Actualizado el 8 oct 2026 · NCT02013336PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
ReclutandoFase 1/2
Edades de 1 a 30 · Todos los sexos · Actualizado el 6 oct 2026 · NCT06721689Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
ReclutandoFase 2
Hasta los 22 · Todos los sexos · Actualizado el 4 sept 2026 · NCT02559778Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
ReclutandoFase 2
Edades de 1 a 21 · Todos los sexos · Actualizado el 3 sept 2026 · NCT06540963Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Children's Medical Center, Dallas
ReclutandoFase 1/2
Hasta los 26 · Todos los sexos · Actualizado el 3 sept 2026 · NCT06465199Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- y 8 más
ReclutandoFase 3
365 Days – 30 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
ReclutandoFase 1/2
12 Months – 30 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
ReclutandoFase 2
12 Months – 21 Years · Todos los sexos · Actualizado el 12 ago 2026 · NCT05489887NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
- Texas Children's Hospital, Houston
ReclutandoFase 1
Edades de 1 a 24 · Todos los sexos · Actualizado el 21 jul 2026 · NCT07211737NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center, Fort Worth
ReclutandoFase 2
Edades de 1 a 31 · Todos los sexos · Actualizado el 20 jul 2026 · NCT06450041Neuroblastoma Biology Study
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center - Fort Worth, Fort Worth
ReclutandoEstudio observacional
31 Days – 99 Years · Todos los sexos · Actualizado el 23 mar 2026 · NCT01587300De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.